Arcturus Therapeutics (NASDAQ:ARCT) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Arcturus Therapeutics (NASDAQ:ARCT) in a research report sent to investors on Tuesday morning, Benzinga reports. HC Wainwright currently has a $63.00 price objective on the biotechnology company’s stock.

ARCT has been the subject of a number of other reports. Leerink Partners started coverage on Arcturus Therapeutics in a report on Monday, August 12th. They set an outperform rating and a $70.00 price target for the company. Cantor Fitzgerald reiterated an overweight rating on shares of Arcturus Therapeutics in a research report on Monday, September 9th. Finally, Leerink Partnrs upgraded shares of Arcturus Therapeutics to a strong-buy rating in a report on Monday, August 12th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of Buy and a consensus price target of $71.40.

Arcturus Therapeutics Trading Down 3.6 %

Shares of ARCT opened at $23.88 on Tuesday. The firm has a 50-day moving average price of $21.02 and a 200 day moving average price of $26.25. Arcturus Therapeutics has a 12-month low of $17.52 and a 12-month high of $45.00. The firm has a market capitalization of $643.14 million, a P/E ratio of -6.11 and a beta of 2.61.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($1.85) by $1.21. The firm had revenue of $49.86 million for the quarter, compared to analyst estimates of $21.00 million. Arcturus Therapeutics had a negative net margin of 41.21% and a negative return on equity of 25.47%. During the same quarter in the previous year, the company earned ($1.98) EPS. Equities research analysts predict that Arcturus Therapeutics will post -2.6 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Arcturus Therapeutics

Institutional investors have recently modified their holdings of the business. SG Americas Securities LLC acquired a new position in Arcturus Therapeutics during the 3rd quarter worth $191,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Arcturus Therapeutics in the 2nd quarter valued at about $142,000. Scientech Research LLC acquired a new position in shares of Arcturus Therapeutics during the second quarter worth about $374,000. Millennium Management LLC increased its stake in shares of Arcturus Therapeutics by 250.1% during the second quarter. Millennium Management LLC now owns 555,024 shares of the biotechnology company’s stock worth $13,515,000 after buying an additional 396,505 shares during the period. Finally, Deerfield Management Company L.P. Series C acquired a new stake in Arcturus Therapeutics in the second quarter valued at approximately $958,000. Institutional investors and hedge funds own 94.54% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.